Top Story Today
Novo Nordisk's Next-Gen Obesity Shot Just Lost to Zepbound, and Wall Street Was Ruthless
CagriSema, the dual-mechanism drug Novo Nordisk built to reclaim the obesity crown, failed to match Eli Lilly's Zepbound in a Phase 3 head-to-head trial. Zepbound patients lost 25.5% of their body weight versus 23% for CagriSema, missing even the non-inferiority bar (the lowest threshold, proving it's "close enough"). Novo's stock cratered roughly 16% in a single session, falling to 2021 levels. At least seven analysts slashed price targets. The result hands Lilly the cleanest marketing pitch in pharma: "Our drug beat theirs."
Why it matters: In a two-horse obesity market projected to exceed $100 billion by the mid-2030s, this trial reshapes the competitive hierarchy and puts enormous pressure on Novo's pipeline (especially amycretin) to close the efficacy gap before Lilly's next-gen drugs extend the lead even further.
Read more →The Obesity Arms Race at ADA 2026
Lilly's Triple-Agonist Retatrutide Just Posted 28% Weight Loss
While Novo was licking its wounds, Lilly showed Phase 3 data for retatrutide that blew past every GLP-1 on the market. The triple-agonist (GLP-1/GIP/glucagon) delivered 28.3% average weight loss at 80 weeks, approaching bariatric surgery territory. A new side effect, tingling sensations called dysesthesia, hit about 10-20% of patients and will need close FDA scrutiny. Filing expected late 2026.
Read more →Zepbound's Top Dose Just Got 52% Cheaper Through LillyDirect
Lilly capped Zepbound doses at $299–$449/month through its direct-to-patient platform, slashing the 15 mg price from $1,049. The timing is strategic: compounding pharmacies are shut down, Novo is undercutting with $399 Wegovy HD, and millions of displaced patients need a new option. Wall Street called it earnings-neutral with meaningful volume upside.
Read more →Pfizer's Monthly Obesity Shot Delivers 12% Placebo-Adjusted Weight Loss
After killing two oral obesity candidates over safety issues, Pfizer showed up to ADA with berobenatide, a once-monthly injection that posted 12.3% placebo-adjusted weight loss at 28 weeks with notably clean tolerability. Not category-defining, but in a $100 billion market, a monthly shot with mild side effects could carve out real share. Ten Phase 3 trials planned for 2026.
Read more →Roche's Petrelintide: The Obesity Drug That Barely Makes You Nauseous
Roche and Zealand's amylin-based obesity drug posted a near-placebo tolerability profile in Phase 2, with no patients quitting over GI issues at the maximally effective dose. Weight loss (10.7% at 42 weeks) won't win arms races, but in a world where 50-70% of GLP-1 patients quit within a year, a drug patients actually stay on could become the backbone of future combination regimens.
Read more →Clinical and Regulatory
Sarepta's Gene Therapy Gets the FDA's Scariest Warning Label
Two patient deaths from liver failure earned Elevidys a black box warning, and the FDA narrowed its approved population to ambulatory patients only. On the same day, Sarepta cut 500 jobs (36% of staff) and pivoted its pipeline toward siRNA. The stock somehow surged 30% after hours because investors had priced in a full market withdrawal. The gene therapy field's class-wide safety concerns just got louder.
Read more →The FDA Wants Gene Therapy Makers to Stop Starting From Scratch
New draft guidance lets gene therapy developers reuse manufacturing, safety, and clinical data across programs that share the same editing platform or viral vector. For a field where approval takes 6-12 years and success rates hover around 9%, cutting redundant work could meaningfully compress timelines. Platform companies with multiple programs off the same backbone stand to benefit most.
Read more →This UC Drug's 51% Remission Rate Has a Cancer Problem
Abivax's obefazimod posted the highest maintenance remission rate ever seen in an ulcerative colitis trial (51% vs. 10% placebo). But seven malignancies in the high-dose arm sent the stock down 40-45%. Analysts are split on whether it's a real signal or noise, and the FDA advisory committee meeting that's now likely will determine the drug's commercial ceiling.
Read more →Deals and Infrastructure
GSK Buys a Tiny Lab to Win the Oligonucleotide Arms Race
GSK acquired Elsie Biotechnologies for up to $50 million, not for a drug, but for its high-throughput oligonucleotide discovery platform. The deal caps a $700 million+ spending spree on RNA-based medicine infrastructure. Oligo therapeutics have dominated the biggest RNA-therapy deals in the past year, and the market is projected to roughly reach $18 billion by 2030.
Read more →Britain Bets Big on Life Sciences Infrastructure
The UK announced a major new life sciences R&D push as part of a broader £2 billion investment plan. The context makes it urgent: Merck just scrapped a £1 billion UK expansion, and U.S. biotech venture funding outpaces all of Europe roughly four or five to one. The real question is whether Britain can stop the talent drain in the meantime.
Read more →